Cannabis News
The Marijuana Misinformation Machine – How Politicians Plan to Block Cannabis Legalization
In recent years, we’ve heard politicians clamoring about the dangers of “misinformation” and “disinformation,” with some even calling for regulations on free speech. But these same politicians seem to have a glaring blind spot when it comes to their own history of spreading falsehoods, particularly regarding cannabis.
For over a century, the U.S. government has been the primary purveyor of marijuana misinformation, running smear campaigns that have shaped public perception and policy. From outlandish claims about cannabis-induced insanity in the 1920s to Nixon’s war on drugs in the 1970s, official channels have consistently peddled propaganda over facts.
The irony is palpable. While decrying the spread of misinformation in the digital age, many politicians conveniently ignore the government’s long-standing role as the chief architect of cannabis myths and misconceptions.
Today, we’re diving into this rich history of government-sponsored cannabis disinformation and examining recent findings from the National Institutes of Health (NIH) that reveal a telling trend: Americans don’t trust official sources when it comes to marijuana information.
As we peel back the layers of propaganda and explore the roots of public mistrust, we’ll see how the government’s own actions have undermined its credibility on this issue. The marijuana misinformation machine has been running for decades, and it’s time to set the record straight.
So buckle up, dear readers. We’re about to embark on a journey through the smoky haze of cannabis history, separating fact from fiction and exposing the hypocrisy at the heart of the war on drugs. Let’s dive in!
In an era where information is at our fingertips, it’s ironic that when it comes to cannabis, Americans are turning away from traditional sources of medical knowledge. A recent study published in the Journal of Cannabis Research, partially funded by the National Institute on Drug Abuse, has shed light on this phenomenon, revealing a startling lack of trust in government and medical sources for cannabis information.
The study, which surveyed 1,161 adults nationwide, found that only 4.7% of respondents relied on government agencies for cannabis-related information. Even more surprisingly, health and medical care providers fared only slightly better at 9.3%. Instead, the majority of people turn to friends and family (35.6%) or websites (33.7%) for their cannabis knowledge.
This mistrust isn’t unfounded. For decades, the U.S. government has been the primary purveyor of cannabis misinformation, running smear campaigns that have shaped public perception and policy. This propaganda has not only affected the general public but has also seeped into medical education, creating a knowledge gap among healthcare providers.
The study highlights this medical ignorance, noting that only 9% of medical schools in 2016 offered cannabis-specific curricula. This lack of education isn’t necessarily the fault of individual healthcare providers, but rather a systemic issue rooted in years of government-sponsored misinformation. Many medical professionals simply haven’t had the opportunity to update their “firmware” on the subject matter.
As cannabis use continues to rise and legalization spreads across the country, it’s clear that the medical community needs to catch up. The study authors emphasize the “strong need for better clinician education, public outreach strategies, and improved communication between patients and clinicians about cannabis.”
However, addressing this knowledge gap isn’t as simple as updating medical textbooks. A separate study published in PeerJ Life & Environment reveals a troubling trend in biomedical education materials. The study found that many authors of influential medical textbooks have undisclosed financial conflicts of interest, including patents and compensation from pharmaceutical companies.
This ethical conflict of interest raises questions about the objectivity of medical education materials, particularly when it comes to topics like cannabis that could potentially threaten pharmaceutical profits. As we push for better cannabis education in medical schools, we must also address these underlying conflicts of interest to ensure that future healthcare providers receive unbiased, evidence-based information.
The age of mistrust in official sources of cannabis information presents both challenges and opportunities. While it’s concerning that so few people turn to medical professionals for guidance, it also highlights the need for a major overhaul in how we educate both the public and healthcare providers about cannabis.
As we move forward, it’s crucial that we address the legacy of misinformation, update medical curricula, and ensure transparency in medical education materials. Only then can we hope to bridge the trust gap and provide accurate, unbiased information about cannabis to those who need it most.
The prohibition of cannabis in the United States is a tale woven with threads of deception, racism, and political manipulation. From its inception, the campaign against marijuana has relied on sensationalism and outright lies to justify its existence.
As NORML points out, the initial push for cannabis criminalization had little to do with public health or safety. Instead, it was fueled by xenophobia and racist rhetoric. A prime example is a 1927 New York Times story headlined “Mexican Family Goes Insane,” which farcically claimed that a widow and her children were driven insane by eating the “marihuana plant.” Such sensationalist reporting was common, with a 1933 academic paper in The Journal of Law and Criminology asserting that marijuana use inevitably resulted in “incurable” insanity and death.
At the forefront of this misinformation campaign was Harry J. Anslinger, America’s first “Drug Czar.” Anslinger successfully lobbied Congress to ban cannabis nationwide in 1937, relying heavily on racist rhetoric. He claimed, “There are 100,000 total marijuana smokers in the U.S., and most are Negroes, Hispanics, Filipinos, and entertainers.” He even went so far as to assert that marijuana caused “white women to seek sexual relations with Negroes, entertainers, and any others.”
The weaponization of cannabis misinformation reached new heights during the Nixon administration. Despite privately acknowledging that cannabis wasn’t “particularly dangerous,” Nixon and his team publicly doubled down on the supposed marijuana threat for political gain. John Ehrlichman, Nixon’s domestic policy chief, later admitted the true motives behind their actions: “We couldn’t make it illegal to be either against the (Vietnam) war or Black, but by getting the public to associate the hippies with marijuana and Blacks with heroin… we could disrupt those communities.”
This legacy of lies continued well into the late 20th century with programs like D.A.R.E. (Drug Abuse Resistance Education), which perpetuated exaggerated claims about marijuana. The “lazy stoner” stereotype, heavily promoted by these campaigns, has been debunked by recent studies showing that cannabis users tend to be more active than their non-using counterparts.
Given this extensive history of deception, is it any wonder that people don’t trust the government on cannabis-related information? The federal government didn’t just create fake studies; they actively stonewalled legitimate research to sustain a policy founded on lies and misinformation. This deliberate suppression of scientific inquiry has had far-reaching consequences, hindering our understanding of cannabis and its potential benefits for decades.
The damage caused by this misinformation campaign extends beyond public perception. It has shaped policy, driven mass incarceration, and stifled potentially life-changing medical research. The classification of cannabis as a Schedule I substance, alongside drugs like heroin, flies in the face of scientific evidence and has been a major obstacle to comprehensive study.
This is why simply rescheduling cannabis is not enough. What we need is a complete dismantling of the Controlled Substances Act (CSA). We need an independent, unbiased group to research these substances without the weight of decades of political baggage. It’s time to rethink our approach as a society to drug consumption and remove the regulatory hurdles that have long impeded research and product development.
The path forward requires more than just correcting misinformation; it demands a fundamental shift in how we approach drug policy. We must acknowledge the racist and politically motivated roots of cannabis prohibition and work to undo the harm caused by decades of lies. Only then can we hope to develop a rational, evidence-based approach to cannabis that prioritizes public health, individual liberty, and scientific truth over political agendas and corporate interests.
As we move into a new era of cannabis policy, let’s learn from the mistakes of the past. It’s time to replace fear-mongering with facts, propaganda with peer-reviewed research, and prohibition with sensible regulation. The history of cannabis prohibition in America is indeed a history of lies – but it doesn’t have to be our future.
After more than half a century of lies, misinformation, and propaganda, the U.S. government and healthcare establishment face a monumental task: regaining the public’s trust on cannabis and drug policy. But here’s the harsh truth – they can’t. At least, not without radical, systemic change.
The problem runs deep. How can we trust pharma-sponsored studies when there’s an obvious conflict of interest? How can we believe government agencies that have consistently prioritized political agendas over scientific truth? The credibility well has run dry, and refilling it will require more than just a change in rhetoric or policy tweaks.
The only path forward is a complete overhaul of our approach to drugs in America. This means dismantling the Controlled Substances Act (CSA) and renegotiating how we produce, distribute, and regulate drugs in the U.S. Until we take this drastic step, public trust in government agencies and healthcare providers on these issues will remain – justifiably – at rock bottom.
We need to create a new system built on transparency, scientific integrity, and genuine concern for public health. This means severing the ties between drug policy and corporate interests, political agendas, and law enforcement quotas. It means funding independent research, free from the influence of pharmaceutical companies or government agencies with a vested interest in maintaining the status quo.
Let’s be clear: you can’t trust a politician who takes money from Big Pharma or law enforcement unions to make unbiased decisions about drug legalization. That’s like trusting an obese person’s advice on losing weight – the conflict of interest is too glaring to ignore.
Moving forward, we need to demand full transparency in medical education, research funding, and policy-making. We need to elevate voices that have been historically marginalized in these discussions, including those of cannabis users, medical patients, and communities disproportionately affected by the war on drugs.
The road to rebuilding trust will be long and challenging. But it starts with acknowledging past wrongs, committing to radical change, and putting the wellbeing of individuals and communities above political and corporate interests. Only then can we hope to create a drug policy that truly serves the American people.
SOURCES:
MISINFORMATION IN YOUR FEED, YOU BET, READ ON…
Cannabis has so many compounds, and two that have been making the rounds lately are HHC and Delta 9 THC. They’re not the same thing, even though they’re both cannabinoids that interact with the body’s endocannabinoid system. Some people want a mild, steady experience, while others might be looking for something more intense. Understanding these two can help you figure out what’s right for you.
What Is HHC?
HHC, short for hexahydrocannabinol, is a hydrogenated version of THC. It’s not something you’d find naturally in large amounts in cannabis plants. Instead, it’s made through a process that adds hydrogen molecules to THC. The result? A more stable compound that’s less prone to breaking down when exposed to heat or UV light.
How HHC Is Made
Think of it like a science experiment. HHC is usually created in a lab by taking Delta 9 or Delta 8 THC and using hydrogenation—basically, combining it with hydrogen under pressure and in the presence of a catalyst. This process changes its structure while keeping its effects somewhat similar to THC.
Common Uses and Effects of HHC
People who use HHC say it’s somewhere between Delta 8 and Delta 9 in terms of effects. It’s often described as relaxing but without being overly sedative. You might feel a light buzz, reduced stress, or mild euphoria. Some even claim it helps with discomfort or improving sleep, but solid research is still catching up. Since it’s less potent than Delta 9, it’s often favored by those who want a manageable experience without the strong psychoactive punch.
If you’re interested in trying HHC and Delta 9 for yourself, check out their wide range of products at trycandycloud.com. They’ve got everything from gummies to disposable vapes, all crafted for a smooth experience.
What Is Delta 9 THC?
Delta 9 THC is the main psychoactive compound in cannabis. It’s the reason you feel “high” when you use weed. Chemically speaking, Delta 9 has a double bond in its ninth carbon chain, which plays a big role in how it interacts with your brain.
Natural Occurrence in Cannabis
This one is straightforward: Delta 9 is found in high concentrations in marijuana plants. It’s what most people think of when they hear “THC.” Unlike HHC, there’s no need for a lab process—it’s already there. Hemp plants, however, contain much lower levels of Delta 9 THC, which is why it’s primarily extracted from marijuana.
Common Uses and Effects of Delta 9 THC
The effects of Delta 9 are well-documented. Depending on the dose, you might feel euphoria, increased appetite, or deep relaxation. For medical users, it’s often used to manage chronic pain, nausea, and other conditions. It’s also been studied for its potential benefits in anxiety relief, though higher doses might have the opposite effect, causing paranoia. Delta 9 THC is versatile, but it’s not without its risks, particularly for new users or those sensitive to its psychoactive effects.
Key Differences Between HHC and Delta 9 THC
Chemical Structure and Composition
The main difference is in their structure. Delta 9 THC has that iconic double bond, while HHC’s hydrogenation makes it more stable. This difference might not mean much to the average person, but it’s why HHC is less likely to degrade over time.
Potency Levels
Delta 9 THC is generally more potent. HHC might require a higher dose to get a comparable effect, but some people prefer its lighter touch. Potency differences can also depend on the method of consumption, with edibles typically providing a stronger, longer-lasting effect compared to vaping or smoking.
Duration of Effects
Both last a few hours, but some users report that HHC’s effects fade more gradually. Delta 9, on the other hand, can have a sharper comedown. HHC’s gradual fade makes it appealing for those who want a smooth end to their experience.
Benefits and Drawbacks of HHC and Delta 9 THC
HHC: Pros and Cons
Pros:
- More stable, so it lasts longer on the shelf.
- Effects are milder, making it less overwhelming for beginners.
- Can be a functional option for daytime use.
Cons:
- Limited research, so we don’t know its full impact yet.
- Availability can be hit or miss depending on where you live.
- Legal gray area in many regions.
Delta 9 THC: Pros and Cons
Pros:
- Well-studied with established medical uses.
- Widely available in areas where cannabis is legal.
- Stronger effects make it ideal for experienced users or those with high tolerance.
Cons:
- Higher chance of side effects like anxiety.
- More likely to show up on drug tests.
- Shorter shelf life compared to HHC.
Frequently Asked Questions (FAQ)
Q. Is HHC safer than Delta 9 THC?
Not enough research exists to say definitively, but HHC’s milder effects might make it feel safer to some users.
Q. Will HHC or Delta 9 THC show up on a drug test?
Yes, both can potentially show up on a drug test, so use with caution if that’s a concern.
Q. Which one is better for recreational use?
That depends on your preferences. HHC is great for a mellow time, while Delta 9 is better if you’re looking for something more intense.
HHC vs. Delta 9: Choosing the Right One for You
The choice comes down to what you’re after. If you want a milder, more laid-back experience, HHC might be a good option. On the other hand, if you’re looking for something stronger or need it for medical reasons, Delta 9 is the way to go. It also depends on what’s legal and available where you are. And always consider your tolerance levels and experience before diving in. If you’re unsure, consult with a knowledgeable dispensary staff.
Resources:
Cannabis News
What Federally Illegal Drug Has Created Almost $10 Billion in Sales Tax Revenue for States in the Last 40 Months?
In a significant development for the burgeoning cannabis industry, the U.S. Census Bureau has reported that states across the nation have collectively amassed over **$9.7 billion** in tax revenue from marijuana sales since mid-2021. This figure underscores the economic impact of legalized cannabis and highlights the growing acceptance of marijuana as both a recreational and medicinal substance in various states. As more states move toward legalization, the financial implications both positive and negative are becoming increasingly evident.
The Landscape of Cannabis Legalization
The journey toward cannabis legalization in the United States has been long and complex. Initially criminalized in the early 20th century, cannabis began to regain acceptance in the late 20th century, particularly for medical use. The first state to legalize medical marijuana was California in 1996, setting a precedent that many states would follow.
By 2012, Colorado and Washington became the first states to legalize recreational cannabis, paving the way for a wave of legalization efforts across the country. As of now, more than 20 states have legalized recreational marijuana, while over 30 states allow medical use. This shift reflects changing public attitudes toward cannabis and recognition of its potential benefits.
Economic Implications of Legalization
The legalization of cannabis has not only transformed social norms but has also created a substantial economic impact. States that have embraced legalization have seen significant increases in tax revenue, job creation, and investment opportunities.
According to the latest Census Bureau report, states like California, Colorado, Illinois, and Michigan have emerged as leaders in cannabis tax revenue generation. These states have implemented various tax structures on marijuana sales, including excise taxes, sales taxes, and local taxes. The revenue generated is often earmarked for essential public services such as education, healthcare, infrastructure improvements, and drug rehabilitation programs.
Breakdown of Tax Revenue by State
As the largest legal cannabis market in the United States, California has been at the forefront of marijuana tax revenue generation. Since mid-2021, California has contributed approximately $2.5 billion to state coffers from cannabis taxes. This revenue is derived from both recreational and medical marijuana sales.
California’s tax structure includes a 15% excise tax on retail sales, along with local taxes that can vary significantly by city and county. The state has allocated a portion of these funds to various programs aimed at addressing issues related to drug abuse and public health.
Colorado was one of the pioneers in cannabis legalization and continues to serve as a model for other states. Since mid-2021, Colorado has generated around $1.8 billion in tax revenue from marijuana sales. The state imposes a 15% excise tax on wholesale marijuana transactions and a 2.9% sales tax on retail sales.
The revenue generated from cannabis taxes has been instrumental in funding education initiatives through the Public School Fund, as well as supporting mental health programs and substance abuse treatment services.
Illinois has seen remarkable growth in its cannabis market since legalizing recreational use in January 2020. In just two years, Illinois has collected approximately $1 billion in tax revenue from marijuana sales. The state imposes a tiered excise tax based on the potency of the product, ranging from 10% to 25%.
The funds collected are allocated to various initiatives, including community reinvestment programs aimed at addressing social equity issues related to past drug enforcement practices.
Michigan’s cannabis market has also flourished since legalization. Since mid-2021, Michigan has generated about $700 million in tax revenue from marijuana sales. The state’s tax structure includes a 10% excise tax on recreational marijuana and a 6% sales tax.
The revenue is utilized for various purposes, including education funding and support for local governments impacted by legalization.
Broader Economic Impact
The legalization of cannabis has led to significant job creation across various sectors. According to industry reports, the legal cannabis market supports hundreds of thousands of jobs nationwide—from cultivation and processing to retail and distribution. As more states legalize marijuana, this trend is expected to continue.
With the growth of the legal cannabis industry comes increased investment opportunities. Entrepreneurs are entering the market at an unprecedented rate, leading to innovations in product development, marketing strategies, and distribution channels. This influx of investment not only benefits individual businesses but also stimulates local economies.
Social Equity Considerations
While the financial benefits of cannabis legalization are clear, it is essential to address social equity issues that arise alongside this new industry. Many states have recognized that communities disproportionately affected by past drug enforcement policies should benefit from legalization efforts.
States like Illinois have implemented community reinvestment programs that allocate a portion of cannabis tax revenues to support communities impacted by previous drug laws. These funds can be used for education initiatives, job training programs, and mental health services—aiming to rectify historical injustices associated with cannabis prohibition.
In addition to financial support for communities affected by past policies, some states are also working to create equitable licensing opportunities for individuals from those communities. By prioritizing applications from minority-owned businesses or those directly impacted by previous drug laws, states can foster a more inclusive cannabis industry.
Challenges Ahead
Despite the significant progress made through legalization efforts, challenges remain on both state and federal levels.
Federal Legalization Uncertainty
One major hurdle is the ongoing conflict between state and federal laws regarding cannabis. While many states have legalized marijuana for recreational or medical use, it remains classified as a Schedule I substance under federal law. This discrepancy creates complications for businesses operating legally at the state level but facing potential federal prosecution.
Efforts toward federal legalization or decriminalization have gained traction recently; however, progress remains slow due to political divisions and differing opinions on drug policy reform.
Regulatory Hurdles
As more states enter the legal cannabis market, regulatory frameworks must evolve to ensure consumer safety while promoting fair competition among businesses. States face challenges related to product testing standards, labeling requirements, advertising restrictions, and taxation policies that can impact market dynamics.
Conclusion
The U.S. Census Bureau reports that states have collected over $9.7 billion in marijuana tax revenue since mid-2021, highlighting the significant economic impact of cannabis legalization. As public acceptance grows, more states are likely to pursue legalization. Despite ongoing challenges, including federal regulations and social equity issues, legalized cannabis is poised to remain a vital part of state economies. Collaboration among government officials, business leaders, and community advocates will be essential for fostering an equitable and sustainable cannabis industry. This evolving landscape not only presents economic growth opportunities but also addresses historical injustices tied to drug policy enforcement, shaping the future of cannabis legislation in the U.S.
WHAT STATES HAVE THE HIGHEST WEED TAXES? READ ON…
HHC vs. Delta 9: Differences & Similarities
DOJ Asks Federal Court To Deny Doctors’ Lawsuit Over Marijuana Rescheduling Hearing To Avoid ‘Undue Delay’
What Federally Illegal Drug Has Created Almost $10 Billion in Sales Tax Revenue for States in the Last 40 Months?
Three Wise Men Give Marijuana Strain Gift Suggestions
Tasmanian Hemp Assoc Bids Goodbye To Australian Hemp Council
Teen Marijuana Use Continues To Drop With Legalization
The Best Cocktails To Make You Feel Festive
Cannabis predictions for 2025: Low prices, high taxes, and hash
Oregon Cannabis: State of the State (2024)
Are MSOs Just Big Pharma on Steriods?
Distressed Cannabis Business Takeaways – Canna Law Blog™
United States: Alex Malyshev And Melinda Fellner Discuss The Intersection Of Tax And Cannabis In New Video Series – Part VI: Licensing (Video)
What you Need to Know
Drug Testing for Marijuana – The Joint Blog
NCIA Write About Their Equity Scholarship Program
It has been a wild news week – here’s how CBD and weed can help you relax
Cannabis, alcohol firm SNDL loses CA$372.4 million in 2022
A new April 20 cannabis contest includes a $40,000 purse
Your Go-To Source for Cannabis Logos and Designs
UArizona launches online cannabis compliance online course
-
Cannabis News2 years agoDistressed Cannabis Business Takeaways – Canna Law Blog™
-
One-Hit Wonders2 years agoUnited States: Alex Malyshev And Melinda Fellner Discuss The Intersection Of Tax And Cannabis In New Video Series – Part VI: Licensing (Video)
-
Cannabis 1012 years agoWhat you Need to Know
-
drug testing1 year agoDrug Testing for Marijuana – The Joint Blog
-
Education2 years agoNCIA Write About Their Equity Scholarship Program
-
Cannabis2 years agoIt has been a wild news week – here’s how CBD and weed can help you relax
-
Marijuana Business Daily2 years agoCannabis, alcohol firm SNDL loses CA$372.4 million in 2022
-
California2 years agoA new April 20 cannabis contest includes a $40,000 purse